DK2402005T3 - Formuleringer med langvarig frigivelse af nalbuphin - Google Patents

Formuleringer med langvarig frigivelse af nalbuphin Download PDF

Info

Publication number
DK2402005T3
DK2402005T3 DK11178912.9T DK11178912T DK2402005T3 DK 2402005 T3 DK2402005 T3 DK 2402005T3 DK 11178912 T DK11178912 T DK 11178912T DK 2402005 T3 DK2402005 T3 DK 2402005T3
Authority
DK
Denmark
Prior art keywords
nalbuphine
sustained
release formulations
formulations
release
Prior art date
Application number
DK11178912.9T
Other languages
English (en)
Inventor
Anand Baichwal
Thomas Sciascia
Donald Diehl
Brian Vogler
Original Assignee
Endo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Pharmaceuticals Inc filed Critical Endo Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2402005T3 publication Critical patent/DK2402005T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK11178912.9T 2005-08-24 2006-08-24 Formuleringer med langvarig frigivelse af nalbuphin DK2402005T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71077205P 2005-08-24 2005-08-24
US77246606P 2006-02-10 2006-02-10
EP06789964.1A EP1931315B1 (en) 2005-08-24 2006-08-24 Sustained release formulations of nalbuphine

Publications (1)

Publication Number Publication Date
DK2402005T3 true DK2402005T3 (da) 2021-03-15

Family

ID=37772363

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06789964.1T DK1931315T3 (da) 2005-08-24 2006-08-24 Depotformuleringer af nalbufin
DK11178912.9T DK2402005T3 (da) 2005-08-24 2006-08-24 Formuleringer med langvarig frigivelse af nalbuphin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK06789964.1T DK1931315T3 (da) 2005-08-24 2006-08-24 Depotformuleringer af nalbufin

Country Status (10)

Country Link
US (2) US8771732B2 (da)
EP (2) EP1931315B1 (da)
JP (1) JP2009506059A (da)
CA (2) CA2620224C (da)
DK (2) DK1931315T3 (da)
ES (2) ES2862573T3 (da)
HU (1) HUE053838T2 (da)
PL (2) PL1931315T3 (da)
PT (2) PT2402005T (da)
WO (1) WO2007025005A2 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515966A (ja) 2001-07-06 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
WO2007048219A2 (en) * 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
PT1931346E (pt) * 2005-09-09 2012-08-14 Angelini Labopharm Llc Composição de trazodona para administração uma vez por dia
JP5453280B2 (ja) * 2007-10-16 2014-03-26 ラボファーム インコーポレイテッド アセトアミノフェンおよびトラマドールを持続的に放出するための二層組成物
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
US20110136921A1 (en) * 2008-08-07 2011-06-09 Nilesh Tanhaji Dumbre Sustained release composition
ES2509497T3 (es) 2008-12-16 2014-10-17 Paladin Labs Inc. Formulación de liberación controlada para evitar un uso indebido
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
DK2701707T3 (da) 2011-04-29 2020-11-02 Univ Rutgers Fremgangsmåde til behandling af dyskinesi
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) * 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
KR20220044385A (ko) * 2012-12-14 2022-04-07 트레비 테라퓨틱스, 인코포레이티드 소양증을 치료하는 방법
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2015192071A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
JP2017100971A (ja) * 2015-11-30 2017-06-08 株式会社ファンケル 錠剤
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
MX2019004804A (es) * 2016-10-25 2019-08-22 Trevi Therapeutics Inc Tratamiento para el prurigo nodula.
IL318587A (en) * 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
US20240131022A1 (en) * 2022-03-11 2024-04-25 John Abernethy Opioid overdose reversal mixtures

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237140A (en) * 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4282215A (en) * 1980-06-17 1981-08-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
US4407804A (en) * 1982-06-30 1983-10-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and indomethacin
US4404209A (en) * 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and sulindac
US4404211A (en) * 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and flurbiprofen
US4404208A (en) * 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and tiflamizole
US4407805A (en) * 1982-06-30 1983-10-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and zomepirac
US4404210A (en) * 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and ibuprofen
US4402962A (en) * 1982-06-30 1983-09-06 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and 4,5-bis(4-methoxyphenyl)-2-(trifluoromethylsulfonyl)-1H-imidazole
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US5013740A (en) * 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
EP0615756B1 (en) 1993-03-15 2001-06-27 National Science Council Nalbuphine esters and long-acting pharmaceutical compositions containing them
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5750534A (en) * 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6806294B2 (en) * 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2226886T3 (es) * 1999-08-31 2005-04-01 Grunenthal Gmbh Forma de administracion de accion retardada que contiene sacarinato de tramadol.
JP2003508420A (ja) * 1999-09-02 2003-03-04 ノストラム・ファーマスーティカルズ・インコーポレイテッド 経口投与に適した、制御された放出の経口用量
EP1207860B1 (en) * 1999-09-02 2007-10-24 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
CN1228043C (zh) 1999-09-30 2005-11-23 爱德华·孟岱尔股份有限公司 用于高溶解度药物的缓释基质
DE60001487T2 (de) 2000-04-27 2003-12-24 Oliver Yoa-Pu Hu Polynalbuphinderivat
WO2001093852A2 (en) 2000-06-09 2001-12-13 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
AU2002314968B2 (en) * 2001-06-08 2006-12-07 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
US6703398B2 (en) 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
JP2005537298A (ja) 2002-08-02 2005-12-08 ペンウェスト ファーマシューティカルズ カンパニー メトホルミンの徐放性製剤
ATE482695T1 (de) * 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
JP2006520392A (ja) * 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
CA2541371C (en) * 2003-10-03 2014-12-16 Atul M. Mehta Extended release formulations of opioids and method of use thereof
US20050165038A1 (en) * 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
US20060111382A1 (en) * 2004-05-17 2006-05-25 Pharmacofore, Inc. Compositions and methods for treating or preventing pain

Also Published As

Publication number Publication date
PL2402005T3 (pl) 2021-11-22
PT1931315E (pt) 2014-01-03
US8771732B2 (en) 2014-07-08
CA2620224A1 (en) 2007-03-01
EP2402005B1 (en) 2020-12-16
US9186330B2 (en) 2015-11-17
EP1931315A2 (en) 2008-06-18
JP2009506059A (ja) 2009-02-12
ES2862573T3 (es) 2021-10-07
ES2441766T3 (es) 2014-02-06
EP2402005A1 (en) 2012-01-04
CA2881739A1 (en) 2007-03-01
PT2402005T (pt) 2021-04-14
WO2007025005A2 (en) 2007-03-01
EP1931315B1 (en) 2013-10-16
WO2007025005A3 (en) 2007-12-21
DK1931315T3 (da) 2014-01-20
HUE053838T2 (hu) 2021-07-28
CA2620224C (en) 2015-11-24
US20140315937A1 (en) 2014-10-23
US20070048376A1 (en) 2007-03-01
PL1931315T3 (pl) 2014-09-30
CA2881739C (en) 2018-01-02

Similar Documents

Publication Publication Date Title
CY2022001I1 (el) Παραγωγα του uk-2a
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
CY2013035I1 (el) Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1778618T3 (da) Syntese af triethylentetraminer
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1720866T3 (da) Fremgangsmåde
DK1858342T3 (da) Fremgangsmåde til fremstilling af ernæringssammensætninger
DK3395338T3 (da) Hurtigt opløsende formulering af cinacalcet-hcl
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
DK1937071T3 (da) Krystallinske modifikationer af pyraclostrobin
DK1879844T3 (da) Fremstilling af natriumdiformiat
CR9144A (es) Formulaciones de benzoxazoles sustituidos
DK1516540T3 (da) Anvendelse af vitamin D-forbindelser
NO20043305D0 (no) Preparation of lodixanol
DE602005016978D1 (de) Quecksilberfreisetzende Zusammensetzungen
EP1879471A4 (en) FLAVOR CONCENTRATES
ATE404546T1 (de) Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen
NO20055643D0 (no) Preparation of lodixanol
EP1906944A4 (en) SKI ANDRIN-B-PREPARATION
EP1838906A4 (en) PREPARATION OF SUSPENSIONS
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
EP1908786A4 (en) 2-cyanoacrylate